Skip to content

Effect of Unani compound formulation in the treatment of Knee joint osteoarthritis

Effect of Habbe Gule Aakh in Osteoarthritis Knee- A Randomised Clinical Trial

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/03/031747
Enrollment
60
Registered
2021-03-05
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M179- Osteoarthritis of knee, unspecified

Interventions

Intervention1: Habbe Gule Aakh(Unani Classic Drug): This compound drug is either manufactured in National Institute of Unani Medicine, Bengaluru, and it can be procured from the market Dosage increase

Sponsors

NATIONAL INSTITUTE OF UNANI MEDICINE
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Diagnosed case of OA Knee Joint as per ACR Criteria (Clinical and Radiological) 2.Patient of either gender. 3.Patients in age groups of 30-60years. 4.Radiologically Grade I,II, III and IV(Kellgren Lawrence grading scale) of OA Knee

Exclusion criteria

Exclusion criteria: 1.Patients below 30years and above 60 years of age. 2.Systemic and metabolic illness like IHD,TB and Malignancy. 3.Patients with other than osteoarthritis 4.H/o Knee injury, surgery, steroid injection in knee joints 5.Pregnancy and lactation 6.Morbid Obesity BMI >40

Design outcomes

Primary

MeasureTime frame
Dose escalation by following assesment 1.Reduction in Pain by using VAS 2.Impoving quality of life assesed by WOMAC (modified) CRD PUNE Timepoint: Follow up:0th ,7th , 14th and 21st Day Duration of Protocol:21days. Duration of study:18 months

Secondary

MeasureTime frame
Dose escalation by following assessment 1.Reduction in Pain by using VAS 2.Impoving quality of life assesed by WOMAC (modified) CRD PUNE Timepoint: Follow up:0th ,7th , 14th and 21st Day Duration of Protocol:21days. Duration of study:18 months If not responding well or adverse event stop the treatment and switchover to standard dose or other therapies

Countries

India

Contacts

Public ContactDR MOHD ALEEMUDDIN QUAMRI

NATIONAL INSTITUTE OF UNANI MEDICINE

drmaquamri@gmail.com9341072974

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026